Beam Therapeutics Inc. (BEAM) Q3 2025 10-Q Quarterly Report
Filed: Nov 4, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR Beam Therapeutics Inc. (BEAM) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 4, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Beam Therapeutics Inc. Q3 2025 10-Q Analysis
Risk Factors
- • New regulatory risk: FDA orphan drug and regenerative medicine advanced therapy designations granted for BEAM-302 in 2025, triggering expanded clinical trial and regulatory requirements
- • Updated clinical risk: BEACON trial interim data on BEAM-101 showed sustained mean total Hb increase to 15.6 g/dL at month six, with no Grade 3+ adverse events reported
- • Legal/licensing risk: $200M upfront and up to $350M in milestone payments under Eli Lilly agreement for Verve programs, with $25M received through Q3 2025
- • Operational risk: Early-stage Phase 1/2 trials underway for BEAM-301 and BEAM-302 with ongoing dose escalation and safety monitoring critical for near-term pipeline progress
- • Financial risk: Collaboration revenue included a $3.8M Apellis cash opt-in fee in Q3 2025, reflecting dependency on partner licensing for near-term cash inflows
Beam Therapeutics Inc. Q3 2025 Quarterly FinancialsXBRL
Revenue
$10M
▼ -32.0% YoY▲ +14.6% QoQ
Net Income
-$113M
▼ -16.6% YoY▼ -10.2% QoQ
Operating Margin
-1307.6%
▼ -56120bp YoY▲ +11162bp QoQ
Net Margin
-1162.4%
▼ -48492bp YoY▲ +4587bp QoQ
ROE
-11.7%
Total Assets
$1.3B
EPS (Diluted)
$-1.09
▲ +7.6% YoY▼ -10.1% QoQ
Operating Cash Flow
-$81M
▲ +7.5% YoY▼ -6.6% QoQ
Source: XBRL data from Beam Therapeutics Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on Beam Therapeutics Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.